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Pharmaceutical agents targeting the μ opioid receptors (MOR) have been widely used in 
the treatment and management of pain. However, serious side effects and the prevalence of abuse 
have complicated their administration. This has increased the interest of developing 
pharmaceutical agents that selectively bind to the κ opioid receptors (KOR). Recent investigation 
has determined that KOR agonists exhibit a decreased liability for addiction as well as 
respiratory depression in comparison to MOR agonists.
 
Selectively binding antagonists to the 
KOR have only been utilized historically as pharmacological tools. Additionally, KOR 
antagonists show promising potential in therapeutic treatment of depression and anxiety, as well 
as opiate and cocaine addiction.
 
KOR antagonists that are metabolically stable have been shown to penetrate the CNS. 
However, peptide-based KOR-selective antagonists are metabolized by proteases and are 
expected to have a shorter activity than non-peptide KOR-selective antagonists with increased 
metabolic stability. Through the incorporation of unnatural amino acids as well as 
conformational constraints in the C terminus, zyklophin experiences increased enzymatic 
stability. Initial testing has shown that zyklophin crosses the blood brain barrier to antagonize the 
KOR in the CNS with in vivo administration and that its duration of activity after a system dose 
is less than 12 hours, whereas a non-peptide KOR antagonist, such as nor-BNI, exhibits duration 
of activity weeks after a single dose is administered. This prolonged activity complicates its use 
as a pharmacological tool and as a potential therapeutic agent whereby increasing the importance 
of peptide-based KOR antagonist. 
Currently, the FDA has not approved a drug for the prevention of relapse due to cocaine 
addiction. Peptide-based drugs have been shown to be successful pharmaceutical agents 
exhibiting high activity, high specificity, low toxicity, and minimal drug-drug interaction. Due to 
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modifications of the C-terminus, zyklophin has an increased metabolic stability. Thus, zyklophin 
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Cocaine Addiction and Potential Treatment by the κ Opioid 




Cocaine is an illicit, highly addictive narcotic that directly affects the brain by interfering 
with the dopamine transport system. It has had a long history of abuse in America, and over the 
past decade cocaine has become an increasing prominent part of the European drug scene. In 
Europe, cocaine is the most abused illicit stimulant in the southern and western countries and the 
second most abused illicit stimulant in the northern and eastern countries. [1]. Cocaine is derived 
from coca leaves and is sold in two forms: a water-soluble hydrochloride salt and a water-
insoluble freebase. The water soluble hydrochloride salt can be injected intravenously and both 
forms can be snorted or smoked all of which allows for rapid to immediate absorption into the 
body. 
Cocaine affects the neural system in the ventral tegmental area (VTA) of the brain. Nerve 
fibers exist in the VTA that extend into areas of the brain involved in reward. When cocaine 
passes through the blood brain barrier and enters the VTA, dopamine levels rise resulting in 
increased neural activity. In normal brain function, a neuron releases dopamine into a synapse 
where it binds to dopamine receptors on a neighboring neuron sending a signal to that neuron 
relating to reward, reinforcement, motivation, arousal, cognitive control, or motor control. 
Following binding, dopamine is then removed from the synapse and recycled by the 
dopamine transporter. The transporter binds the neurotransmitter and pumps it out of the synaptic 
cleft back into the presynaptic neuron, where it is taken up into storage vesicles. Cocaine binds 
tightly at the dopamine transporter and forms a complex that blocks the transporter's function [2]. 
The dopamine transporter can no longer perform its reuptake function, and thus dopamine 
accumulates in the synaptic cleft. See Figure 1.1 for a diagram illustrating the mechanism of 
action for cocaine. 
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Cocaine binds in a manner that directly stabilizes the dopamine transporter in the open 
outward-facing conformation, whereas other stimulants stabilize in the closed conformation [2]. 
Cocaine binds in such a way as to inhibit a hydrogen bond innate to the dopamine transporter’s 
function by attaching to the active site of the protein. The hydrogen bond will not form since it is 
then blocked from formation due to the tightly locked orientation of the cocaine molecule. The 
affinity for the transporter is not what is involved in so much as the conformation and binding 
properties to where and how on the transporter the cocaine binds [2]. 
As a result of repeated exposure, cocaine abuse leads to the reward pathway becoming less 
sensitive to positive reinforcement or pleasurable feelings of natural rewards (i.e. food, water, 
exercise, sex) as well as to cocaine itself. As a result, high doses of cocaine, as well as more 
frequent applications, are required to achieve a euphoric sensation. These increased doses and 
more frequent abuses often occur in binge behavior.  Due to the binge behavior, users can and 
usually experience one or more of the following: irritability, restlessness, panic attacks, paranoia, 
or psychosis [3]. 
The National Survey on Drug Use and Health estimates that in 2008 there were 1.9 million 
current cocaine abusers and of which 359,000 were abusing crack cocaine. In 2008, 1.4 million 
Americans met the Diagnostic and Statistical Manual of Mental Disorders criteria for 
dependence or abuse of cocaine in the past 12 months [3]. A Drug Abuse Warning Network 
report showed that in 2008 cocaine was involved in 482,188 of nearly 2 million emergency visits 
due to drug abuse [4]. In 2014 a report showed that the mortality rate of cocaine users is over 
five times greater than for the general population [5]. Additionally, another 2014 report showed 























Figure 1.1 Depiction of the mechanism of action for cocaine 
(modified from www.drugabuse.gov)  
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1.2. Opioid Receptor Pharmacology 
Opioid receptors (the three classical opioid receptors are briefly detailed below) are a group 
of inhibitory G protein-coupled receptors (GPCR) that transverse through the cell membrane 
seven times. GPCRs interact and react to endogenous opioids that are distributed widely in the 
brain, and are found in the spinal cord and digestive tract. The endogenous opioids are 
dynorphins, enkephalins, endorphins, and endomorphins. When a ligand binds to the GPCR it 
causes a conformational change, which allows it to act as a guanine nucleotide exchange factor. 
The GPCR can then activate an associated G protein by exchanging its bound guanine 
diphosphate for a guanine triphosphate [7]. Effector systems activated or blocked upon opioid 




 channels, or phosphoinositol 
turnover [8]. See figure 1.2. 
GPCRs constitute a large protein family of receptors that sense molecules outside the cell and 
activate signal transduction pathways inside the cell [9]. The cyclic adenosine monophosphate 
(cAMP) signal pathway and the phosphatidylinositol signal pathway are the two principal signal 
transduction pathways of G protein mediated signaling [10]. For our purposes we will look 
exclusively at the cAMP pathway. 
The cAMP-response element binding protein (CREB) proteins are activated by 
phosphorylation from various kinases, including protein kinase A (PKA). PKA regulates cell 
metabolism by phosphorylating specific enzymes in the metabolic pathway. PKA is activated 
when regulatory subunits are dissociated due to the conformational changes caused by the cAMP 
binding [11]. 
PKA then activates a CREB protein in the nucleus. The activated CREB protein then binds to 
a cAMP response element region. This binding activates the cAMP response element region, 
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allowing it to switch certain genes on or off. The endogenous ligand dynorphin is regulated by 






Figure 1.2 The seven transmembrane structure of opioid G-protein-coupled receptor. 
Receptor activation by opioid receptor ligands leads to initiation of intracellular transduction 
pathways that include stimulation of potassium efflux and inhibition of adenylyl cyclase. In this 




 channel and 
adenylate cyclase. Used with permission. [12] 
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1.2.1. κ opioid receptors (KOR) 
The KOR is an opioid receptor that is located in the brain, spinal cord, and peripheral sensory 
neurons. In the brain it is found in the hypothalamus, periaqueductal gray, and claustrum. In the 
spinal cord it is found in the substantia gelatinosa [13]. The primary endogenous ligands that 
bind to the KOR are dynorphin A, dynorphin B, and α-neoendorphin [14]. The physiological 
functions of KOR is observed in analgesia, anticonvulsant effects, depression, 
dissociative/hallucinogenic effects, diuresis, dysphoria, miosis, neuroprotection, sedation, stress, 
and addiction control [13,14]. Due to the side effects of dysphoria, diuresis, and hallucinations 
KOR agonists have seen limited clinical utilization [15]. However, over the past decade KOR 
agonists have investigated for their therapeutic potential in the treatment of addiction [16]. The 
relationship between addiction and the KOR/dynorphin system will be a focal point of this work. 
1.2.2.  µ opioid receptors (MOR) 
The MOR is an opioid receptor that is located in the brain, spinal cord, peripheral sensory 
neurons, and the intestinal tract. In the brain it is found in the laminae III and IV of the cortex, 
thalamus, striosomes, periaqueductal gray and rostral ventromedial medulla. In the spinal cord it 
is found in the substantia gelatinosa [13]. A high density of MOR receptors is found in the 
caudate putamen of the basal ganglia. MOR receptors are located presynaptically on primary 
afferent neurons within the dorsal horn of the spinal cord where they inhibit glutamate release 
and hence transmission of nociceptive stimuli [13]. The periaqueductal grey is an area of the 
midbrain involved in the central control of nociceptive transmission. The physiological functions 
of MOR can be observed in analgesia, physical dependence, respiratory depression, miosis, 
euphoria, reduced GI motility, and vasodilation [13,14]. The primary endogenous ligands that 
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bind to the MOR are the opioid peptides endomorphin, endorphin, met-enkephalin, and leu-
enkephalin. 
1.2.3.  δ opioid receptors (DOR) 
The DOR is an opioid receptor that is located in the brain and in peripheral sensory neurons. 
In the brain it is found in the pontine nuclei, amygdala, olfactory bulbs, and the deep cortex [13]. 
DOR utilize enkephalins as its endogenous ligands. DOR receptors are located presynaptically 
on primary afferents where they inhibit the release of neurotransmitters. The physiological 
function of DOR is seen in analgesia, antidepressants, convulsants, physical dependence, and 
respiratory depression [13,14]. The primary endogenous ligand that binds to the DOR are the 
opioid peptides met-enkephalin and leu-enkephalin. 
1.3. Addiction and KOR 
One of the leading views in understanding why the brain becomes addicted is that it strives to 
maintain equilibrium [17]. This concept is defined as allostasis, which is the process of achieving 
stability, or homeostasis, through physiological or behavioral change. Processes that are allostatic 
in nature are thought to alter homeostatic processes. An example of this would be frequent drug 
use changing the homeostatic equilibrium to include the drug. The result is a craving for the 
drug. Since the reward pathway is desensitized with repeated drug abuse, more drug is required 
to maintain homeostasis. Symptoms of drug withdrawal are then experienced when drug use has 
stopped and drug use has become drug abuse. 
The KOR/dynorphin system is involved in the allostatic process. Drugs of abuse have been 
demonstrated to activate the CREB transcription factor. These effects on CREB have been 
associated with the modulatory increases in dynorphin and subsequent dysphoria-like behaviors 
due to KOR activation [18]. Overexpression of CREB in the nucleus accumbens has been shown 
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to decrease the rewarding effects of cocaine [19]. The dynorphin gene is known to be CREB 
regulated [11], and repeated cocaine administration increases its expression in the nucleus 
accumbens and dorsal striatum [20]. 
Dynorphin as a mediator of dysphoria-like behavior implicates activity of this system as one 
of the primary mediators of the anti-reward system following drug withdrawal, drug craving, and 
relapse to drug seeking [21]. KOR activation has been shown to inhibit evoked dopamine release 
in the nucleus accumbens [22], so that activation of this receptor reduces striatal dopamine 
transmission. See Figure 1.3. 
Currently, the FDA has not approved a drug for the prevention of relapse due to cocaine 
addiction [23]. This has increased the interest of developing pharmaceutical agents that 
selectively bind to the κ opioid receptors (KOR) for the treatment of addiction [24]. Recent 
investigations have determined that KOR agonists exhibit a decreased liability for addiction as 
well as respiratory depression in comparison to MOR agonists [23].
 
Selectively binding 
antagonists to the KOR have only been utilized historically as pharmacological tools. 
Additionally, KOR antagonists, which penetrate the blood-brain barrier, show promising 
potential in therapeutic treatment of depression and anxiety, as well as opiate and cocaine 
addiction [23,25]. In rat models, co-administration of KOR antagonists with cocaine inhibited 
the induction of cocaine conditioned place preference [26]. This shows that a KOR antagonist 
can suppress dopamine release between synapses. 
1.4. Zyklophin 
KOR antagonists that are metabolically stable have been shown to penetrate the CNS. 
However, peptide-based KOR-selective antagonists are metabolized by proteases and are 
expected to have a shorter pharmacological activity than non-peptide KOR-selective antagonists 
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with increased metabolic stability. Through the incorporation of unnatural amino acids as well as 







)]Dyn A- (1-11)NH2) exhibits increased enzymatic stability 
against serum proteases [27]. The functionalities at positions 5 and 8 decrease affinity for the 
MOR and DOR resulting in elevated selectivity for the KOR. Low MOR affinity is due to the 
combination of N-benzylTyr
1
 with the [5,8] cyclicization. Without N-benzylTyr
1
 the relative 
affinity of KOR > MOR is only 9-fold. However, with the addition of N-benzylTyr
1
 the relative 
affinity of KOR > MOR is 194-fold [28]. 
Initial testing has shown that zyklophin crosses the blood brain barrier to antagonize the 
KOR in the CNS following in vivo administration. Zyklophin’s duration of activity following a 
systemic dose is less than 12 hours,
 
whereas a non-peptide KOR antagonists, such as nor-BNI, 
exhibits duration of activity up to 28 days after a single dose is administered. This prolonged 
activity of nor-BNI complicates its use as a pharmacological tool and as a potential therapeutic 
agent thereby increasing the importance of peptide-based KOR antagonists
 
[23]. 
Peptide-based drugs have been shown to be successful pharmaceutical agents exhibiting high 
activity, high specificity, low toxicity, and minimal drug-drug interaction [29]. However, 
peptide-based drugs have been under-utilized due to low oral bioavailability. Due to 
modifications of the C-terminus and address domain, zyklophin has an increased metabolic 
stability, high KOR selectivity, and antagonist activity. Thus, zyklophin is a good lead 
compound for the development of potential treatments of cocaine and opioid addiction and 
relapse. 
 In this thesis work, zyklophin was subcutaneously administered to CD1 mice and the  
pharmacokinetics were investigated. Mice were sacrificed at specific timepoints post-dose and 1 
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mL of blood was collected via cardiac puncture. Following blood collection, the samples were 
immediately centrifuged and the plasma was collected. Then formic acid was added to the 
plasma sample to achieve a final formic acid concentration of 1%. Samples were then stored at  
-80°C until the time of analysis. The samples were analyzed via liquid chromatography coupled 
to tandem mass spectrometry (LC-MS/MS) to determine the concentration of zyklophin in each  
sample. In the following chapter, LC-MS/MS will be discussed as well as the results of the 
analysis of the plasma samples.  
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Figure 1.3 Model by which the dynorphin/kappa system could counteract cocaine-induced 
dopamine release. Cocaine administration elevates dopamine levels. Binding of dopamine on 
the D1 receptor activates the cAMP/PKA/CREB pathway which leads to dynorphin (DYN) 
synthesis. Binding of DYN to KOR located on dopamine terminals exert an inhibitory effect on 
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Development of an LC-MS/MS Method for the Quantitation of 
Zyklophin in Mouse Plasma 
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2.1 Introduction  
Liquid chromatography in conjunction with triple-quadrupole tandem mass spectrometry 
(LC-MS/MS) is a highly effective method for the quantitation of peptides and proteins in a 
biological matrix [1]. It is widely utilized in industry as well as in academia. LC-MS/MS has 
been employed to investigate pharmacokinetics, pharmacodynamics and the stability of peptide-
based pharmaceuticals [2,3]. There are many steps that are involved in the quantitation of a 
peptide in a plasma sample by LC-MS/MS. These include: sample preparation, liquid 
chromatography (LC) separation, analyte ionization, precursor ion selection, fragmentation, 
product ion selection and ion detection. 
One of the more challenging problems that analytical chemists face is isolation of analyte(s) 
of interest from the sample matrix, in this case plasma [4]. Many problems can arise from a 
plasma sample that has not been properly prepared prior to injection into an LC-MS/MS platform. 
These problems include: matrix effects (i.e. ion suppression or enhancement), interferences, and 
development of high back pressures due to the instrument clogging and contamination. There are 
three main techniques that are employed for isolation of a peptide from its matrix for LC-MS/MS 
analysis: protein precipitation, liquid-liquid extraction, and solid phase extraction. 
Liquid chromatography is a technique that can be used to separate each component in a 
sample mixture. When combined with a selective detector (e.g. tandem mass spectrometry) LC is 
a powerful tool that allows us to identify and quantify each component in the sample. A typical 
gradient LC system uses high pressure pumps to pass solvents of known composition (mobile 
phase) to an injector where a sample of unknown composition is injected onto a column that 
contains a packing material (stationary phase) that separates the analyte(s) based on their 
chemical and/or physical properties. For separation to occur each component of the sample, 
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including the analyte(s), must have a different affinity for the stationary phase. The separation is 
based on the equilibrium of the compound between the stationary phase and the mobile phase. If 
the interaction or affinity for the stationary phase is different for each component, then the 
elution of each component will occur at different times depending on how long each component 
spends in the stationary phase. All molecules spend the same amount of time in the mobile phase. 
There are many different types of stationary phases including polar, nonpolar, ionic and affinity 
supports. The analytical column used in this work separates compounds based on their 
hydrophobicity and will be discussed in greater detail below. 
Upon elution from the column, the mobile phase carries the analyte to the ion source of the 
mass spectrometer. Ionization of the analyte occurs when the molecule acquires a positive or 
negative charge due to the gain or loss of a proton at the ion source. Upon reaching the source, 
the mobile phase is vaporized with a pressurized neutral gas (i.e. nitrogen or argon) at high 
temperatures. A voltage is then applied to cause ionization of the analytes of interest. This 
method is called electrospray ionization and will be discussed in greater detail below. 
Once ionized, the analyte goes through the first quadrupole (Q1) of the triple-quadrupole 
mass spectrometer. In Q1, the analyte can exist in several charged states. One of the charge states 
is selected usually based on ion intensity and prevalence. This ion is then accelerated into the 
second quadrupole (Q2) using an electrical potential. In Q2, also called the collision chamber, 
the accelerated ion collides with neutral gas (e.g. nitrogen or argon) causing fragmentation. Upon 
fragmentation, the fragments are then accelerated into the third quadrupole (Q3). In Q3, there 
can be many different fragments produced from the original analyte. These are called product or 
daughter ions. As a result, product ion(s) are selected based on ion intensity and prevalence. 
Product ion selection and detection will be discussed below. 
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2.2 Sample Preparation Techniques in LC-MS/MS 
Blood, plasma and serum contain proteases and other enzymes that can degrade proteins 
and peptides. In addition to this, peptides and proteins can undergo various pathways of chemical 
degradation such as oxidation, reduction, β-elimination and hydrolysis (typically of the peptide 
bond) [5]. To suppress enzymatic activity and chemical degradation, samples can be treated in 
various ways including: temperature control (e.g. sample handling on ice), pH control (acidifying 
samples with formic or hydrochloric acid), utilizing various coagulants (EDTA vs. sodium 
heparin), or the addition of specific enzyme inhibitors. 
The presence of endogenous proteins in a sample can result in variable MS/MS and 
chromatographic behavior. More than 90% of the endogenous proteins found in plasma are 
comprised of only a few different high-abundance proteins. The major protein is serum albumin, 
which has a plasma concentration of 30–50 mg/ml. This accounts for approximately 60% of total 
serum protein [6,7]. The second most abundant proteins are immunoglobulins. When considering 
the presence of all immunoglobulins, they combine to account for up to 30% of plasma protein. 
Thus, achieving separation of the analyte from endogenous proteins prior to MS/MS is essential 
to avoid matrix effects or an overwhelming number of interfering peaks [6,7]. 
Endogenous proteins and peptides are difficult to eliminate from samples due to their 
chemical similarity to the target analytes. The 20 most abundant amino acids all possess the 
characteristic carboxylic acid and amine functional groups, and differ only by the group on the 
alpha carbon, which imparts the unique chemical characteristics. Most large peptides and 
proteins contain a mixture of all the amino acids, and therefore identifying analyte-specific 
chemical properties to exploit for sample preparation can often be challenging. As endogenous 
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proteins are usually much larger than therapeutic peptides and exhibit tertiary structure, the 
simplest way to eliminate proteins is through protein precipitation or size exclusion 
chromatography.  
2.2.1 Protein Precipitation 
A commonly utilized protein precipitation method is salt induced precipitation. At a low salt 
concentration, the solubility of proteins increases slightly. However, at high salt concentrations, 
the solubility of the proteins drops sharply causing the proteins to precipitate. High salt 
concentrations compress the solvation layer, which increases protein-protein interactions. As the 
salt concentration of a solution is increased, the charges on the surface of the protein interact 
with the salt, not the water. This causes the hydrophobic regions on the protein surface to 
become exposed causing the protein to precipitate out of solution. However, this method is not 
utilized with mass spectrometry due to the interference of the salt in analysis.  
A second method of precipitation of proteins in plasma is by changing the pH of the sample 
solution. Precipitation occurs due to the effect of pH on the different functional groups on a 
protein. At the isoelectric point (pI), the net charge on the protein is zero. Proteins vary widely in 
their pI. To isolate a particular protein from solution, at pH = pI, the protein will no longer be 
soluble and will precipitate out of solution. The other option is to use extremes in pH. At low or 
high pH values, the tertiary structure of the protein is altered due to the changes in electrostatic 
interactions, causing the protein to precipitate. This can be accomplished by the addition of an 
acid or base to a sample to denature the proteins. 
A third method is the addition of a water-miscible organic solvent. Organic solvents 
precipitate proteins by reducing the dielectric constant of the medium. Organic solvent molecules 
usually bind to specific hydrophobic residues on the protein molecule. This disrupts the 
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hydrophobic interactions that maintain the protein’s tertiary structure leading to precipitation. In 
this approach, precipitation involves mixing the plasma or serum sample with a water-miscible 
organic solvent (often acetonitrile or methanol) to achieve an organic solvent composition of 
approximately 75% [8]. Endogenous proteins are precipitated and can be removed from the 
sample by centrifugation. Proteins and peptides precipitate at varying concentrations of organic 
solvent. Large proteins (>100 kDa) typically precipitate at >30% solvent, whereas smaller 
proteins usually require a greater proportion of solvent to precipitate, and small peptides often do 
not precipitate at all [1]. 
When using acetonitrile, as little as a 50% final solvent composition still achieves >90% 
precipitation. Acetonitrile has been shown to be a superior organic plasma protein precipitant at 
volume ratios <2:1 (precipitant:plasma) [9]. This half-aqueous precipitation has been reported to 
help maintain the solubility of small polar peptides, while precipitating larger endogenous 
interferences [8]. In contrast, peptides generally do not precipitate at all with organic solvents as 
they are small and lack significant tertiary structure. Peptides smaller than approximately 2.5 
kDa tend to behave similar to small polar molecules with respect to their extractability and LC–
MS/MS behavior, although they often demonstrate a stronger tendency for adsorption, 
insolubility and protein binding [1]. 
Upon protein precipitation, the sample is centrifuged and the supernatant is extracted. 
Depending on the mobile phase utilized in the LC method, the extracted aqueous layer may be 
ready for injection into the LC. However, if the final sample solution is incompatible with the 
desired mobile phase or analytical column, further sample preparation steps will be required. In 
this case, to achieve a desirable final sample solution composition, the sample can be dried under 
inert gas (e.g. nitrogen or argon) or under vacuum and then reconstituted in a solution that is 
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more compatible with the selected mobile phase and analytical column. Depending on the 
difficulty of ionization and the sensitivity of the method, these dried samples can be reconstituted 
in smaller volumes to achieve higher concentrated samples to analyze. 
2.2.2 Liquid-Liquid Extraction 
 Liquid-liquid extraction (LLE) is also known as partitioning or solvent extraction. LLE is 
a technique in which compounds are separated based on their relative solubility in two 
immiscible liquids. For our purposes we will consider water and a water-immiscible organic 
solvent. Since water is very polar, a non-polar organic solvent, such as methyl tert-butyl ether or 
n-butyl chloride, should be chosen. The distribution or partition coefficient (K) is a quantitative 
measure of how a compound will distribute between an aqueous and organic phase. This 
coefficient is the ratio of the solubility of the dissolved solute. Essentially, K is the ratio of 
concentrations of the solute in the two different solvents once the system reaches equilibrium. 
The larger the value of K, the more selective a solution will be for any given compound. 
 Following the addition of the organic solvent and mixing of the two layers, the sample is 
centrifuged to separate the two liquids. Removal of the organic layer can be accomplished in two 
ways. One method is to manually remove the organic layer by pipetting. A second method is to 
rapidly freeze the aqueous layer, typically in a dry-ice acetone bath. Following separation of the 
organic solvent layer, the solvent is evaporated under inert gas or vacuum and the residue is 
reconstituted with a solution that is compatible with the mobile phase and analytical column used 
for the liquid chromatography separation. However, it should be noted that LLE is a poor method 
for the isolation of peptides and proteins as the organic solvents employed can cause 
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denaturation of the larger peptides and proteins. Only highly hydrophobic membrane bound 
peptides would be extracted in LLE. 
2.2.3 Solid Phase Extraction 
 Solid phase extraction (SPE) is a sample preparation method that separates components 
that are present in a solution according to their physical and chemical properties. SPE utilizes a 
sorbent that exhibits specific properties that result in selective binding with the solute of interest. 
As a result, as solution is passed through the sorbent, the solute of interest will remain within the 
sorbent structure while impurities of the solution will pass through. There are many types of SPE 
sorbents. These include ion exchange, size exclusion, normal phase, hydrophilic interaction,  
reversed-phase, and HLB (a polymeric sorbent containing both hydrophobic and hydrophilic 
character). 
 In this work the polymer-based reversed-phase Oasis HLB 96-well Plate, 30 mg sorbent 
per well, 30 µm particle size sorbent was selected due to its optimal sensitivity for therapeutic 
peptide analysis and reduced matrix effects which yields greater selectivity. The steps involved 
in reversed-phase SPE include but are not limited to: conditioning/wetting sorbent with, a wash 
step, a loading step, a wash step, and elution. In the conditioning step a polar solvent is added to 
the column in order to wet the sorbent, allowing for efficient wetting of the surface. Following 
the conditioning step, the sorbent is washed with water to remove all traces of the solvent and to 
wet the silica surfaces that were penetrated by the solvent. At this point, the sample is then 
loaded and passed through the column. Upon loading, the column will be washed several times 
with various solutions, usually an aqueous or a low organic solvent composition solution, to 
clean the column of hydrophilic impurities in the sample. 
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Following the washing steps, the solute of interest can be eluted off the column with a 
solution containing a high percentage of organic solvent. If the final eluted sample solution is 
incompatible with the mobile phase or analytical column used for the separation, further sample 
preparation steps will be required. To achieve a final sample solution composition, the solvent 
can be evaporated under an inert gas or a vacuum and then reconstituted in a smaller volume of a 
different solution that is more compatible with the selected mobile phase, analytical column, and 
to improve the limit of detection. The specific method developed for these studies is found in 
Appendix 1. 
2.3 Liquid Chromatography (Reversed-phase) 
Due to the compatibility with plasma samples and aqueous solutions, reversed-phase 
liquid chromatography is ideal for the separation of biological samples. Reversed-phase liquid 
chromatography exhibits less peak tailing than normal phase chromatography because the 
stationary phase has fewer polar or anionic sites that can strongly adsorb a solute. As a result, 
separation is also less sensitive to polar impurities in the mobile phase than the stationary phase 
utilized for normal phase chromatography. A C-18 column was chosen for these studies based on 
its use in previous studies regarding dynorphin peptides [10]. 
The separation mechanism in reversed phase chromatography depends on the 
hydrophobic interaction between the solute molecule present in the mobile phase and the 
stationary phase of the analytical column. The mobile phase conditions used in reversed phase 
chromatography are primarily aqueous. Retention on the column is dependent on interactions 
between the analyte and the hydrophobic stationary phase. Very hydrophilic components of the 
sample do not interact with the stationary phase and elute in the void volume.  
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Reversed phase chromatography is an adsorptive process that relies on a partitioning 
mechanism to effect separation. The analyte molecules partition and establish equilibrium 
between the mobile phase and the stationary phase. The distribution of the analyte between the 
two phases depends on the binding properties of the stationary phase, the hydrophobicity of the 
solute and the composition of the mobile phase. Initial mobile phase compositions are selected to 
favor adsorption of the analyte of interest from the mobile phase to the stationary phase. For both 
isocratic and gradient elution, upon absorption of the analyte, the mobile phase composition is 
modified to favor desorption and elution of the analyte from the stationary phase back into the 
mobile phase. In this case, adsorption is considered the extreme equilibrium state where the 
distribution of solute molecules is essentially 100% in the stationary phase. Conversely, 
desorption is an extreme equilibrium state where the solute is essentially 100% distributed in the 
mobile phase [11]. 
Reversed phase chromatography of biomolecules, especially in biological samples, 
generally requires gradient elution instead of isocratic conditions and, this, therefore, will be the 
focus of this work. In general, peptides and proteins adsorb to the surface of a reversed-phase 
stationary phase under aqueous conditions. However, they desorb from the stationary phase 
within a very narrow window of organic modifier concentration. As a result, the concentration of 
organic solvent passing through the column needs to be controlled to avoid the simultaneous 
elution of the analyte with the impurities and potential interferences. Thus, gradient elution is the 
only practical method for reversed phase separation of complex biological samples [12]. 
The structure of a peptide should be carefully considered in order to select appropriate 
initial mobile phase gradient conditions. After determining which mobile phases are most 
suitable for peptide analysis, the first step in the chromatographic process is to equilibrate the 
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column under suitable initial mobile phase conditions of pH, polarity, and ionic strength. The 
peptide is then eluted by decreasing the polarity of the mobile phase through the addition of 
organic solvents, such as acetonitrile. The initial mobile phase composition must be nonpolar 
enough to dissolve the partially hydrophobic analyte but polar enough to ensure binding of the 
solute to the reversed phase chromatographic matrix of the analytical column. Once the column 
is equilibrated with the correct composition of mobile phases A and B, the sample is injected into 
the analytical column where it interacts with the stationary phase. See Figure 2.1 for a depiction 
of the instrument set-up for gradient elution. 
The next step of the reversed-phase chromatographic process is desorption and elution of 
bound solutes from the analytical column by decreasing the polarity of the mobile phase. 
Decreasing the polarity is accomplished by gradually increasing the percentage of organic 
solvent in the mobile phase by mixing mobile phase A and B. At a specific composition of 
mobile phases A and B, the sample will elute off the column. The gradual decrease in mobile 
phase polarity is achieved by increasing the organic composition of the overall mobile phase by 
increasing the percentage of B. This gradual change in mobile phase composition causes a 
decrease in polarity. As a result, the bound solutes in the column desorb and elute in order of 
their respective hydrophobicity. 
The next step is the washing of the column with a high percentage of mobile phase B 
over a period of time. This step ensures that all lipids and hydrophobic peptides and proteins and 
potential interferences are washed off the column before the injection of the next sample. The 
final step of the chromatographic process is re-equilibration of the LC column. This final step is 
important because it removes residual organic solvent that could otherwise cause poor retention 
of the following sample injection as interference or elevated background noise. Since this can be 
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a time consuming process, mobile phases A and B are typically chosen so that they only differ in 
regards to organic solvent composition to allow for a more rapid and efficient re-equilibration. 
See Figure 2.9 for gradient profile descriptions utilized in this work. 
 
Figure 2.1: Gradient elution instrumentation depiction. Modified from Waters website 
(www.waters.com). 
 
2.4 Electrospray Ionization 
Electrospray ionization (ESI) makes it possible to use liquid chromatography in conjunction 
with mass spectrometry. ESI is considered a soft ionization technique because it does not 
typically cause macromolecules to fragment but causes formation of charged droplets containing 
analyte. It can be utilized in either positive or negative ion mode. Following the formation of 
charged droplets in positive ion mode, the droplets are further desolvated into smaller droplets 
containing newly attached protons. Charged compounds then move to the surface of the droplet 
to minimize Coulombic repulsion. As this occurs, the ions are vaporized and then pass through 
the mass analyzer and into the detector. See Figure 2.2 for a diagram of the ionization process. 
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2.5 Precursor/Product Ion Selection and Fragmentation 
 A triple quadrupole mass spectrometer consists of two quadrupoles in series with a non-
mass resolving quadrupole in between to serve as a cell for collision-induced dissociation. The 
MS experiments of interest in this work are precursor ion scans, product ion scans and multiple 
reaction monitoring. Precursor ions are selected in the first quadrupole (Q1). The ions are then 
accelerated into the collision cell (the second quadrupole), where they are fragmented by 
colliding with nitrogen or argon gas molecules. Upon fragmentation the ions then enter the third 
quadrupole (Q3) where the product ion is selected and detected. 
The product ion of interest is isolated in Q3 according to its mass-to-charge ratio (m/z). The 
quadrupole mass analyzer can also be considered as a mass filter. Direct current (DC) and radio 
frequencies (RF) applied in the quadrupole affect the trajectory of all ions in Q3. Both the DC 
and RF voltages are optimized to allow only ions with a specific m/z to pass through. All other 
ions will not have a stable trajectory through the quadrupole mass analyzer and will collide with 
the quadrupole rods and never reach the detector. 
In these studies, precursor and product ion scans were performed to optimize the instrument 
parameters for our analyte of interest. From the information obtained from these scans, multiple 
reaction monitoring (MRM) was utilized to compare multiple daughter ions for their sensitivity, 
quantitation, and selectivity. See Figure 2.3 for a diagram of precursor and product ion scanning 
and multiple reaction monitoring. 















Figure 2.3 Depictions of precursor ion scan, product ion scan, and multiple reaction monitoring. 




2.6 Materials and Experimental Methods 
2.6.1 Materials 
 Zyklophin and the structurally related N-methyl tyrosine dynorphin (1-11) analog (Figure 
2.4), which was used as the internal standard, were synthesized in Professor Jane Aldrich’s 
laboratory as reported previously.
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 HPLC-grade acetonitrile and Dulbecco’s phosphate buffered 
saline (PBS) were obtained from Fischer Scientific (Pittsburgh, PA, USA), and deionized water 
was obtained from a Milli-Q Synthesis A10 Water Purification System (Millipore, Billerica, MS, 
USA). Formic acid was purchased from Acros Organics (Morris Plains, NJ, USA) at 99.9% 
purity. 
2.6.2 Animals 
 Adult male CD1 mice were obtained from the Jackson Laboratory (Bar Harbor, ME, 
USA). All mice were housed in accordance to the National Institute of Health Guide for Care 
and Use of Laboratory Animals. Adult male CD1 mice, weighing 30-35g, were administered 
zyklophin by the subcutaneous route at 3 mg kg
-1 
in PBS. The dosing solution (0.100 mL) for the 
subcutaneous administration was geared to the weight of the mice. Animals were sacrificed at 15, 
30, 60, 120, 240, 480 and 720 minutes post-dose, and 1.0 mL of blood was obtained via cardiac 
puncture. The blood samples were immediately centrifuged at 15,000 rpm for 15 min to harvest 
plasma. The samples were kept on dry ice and processed on ice. Prior to freezer storage samples 
were treated with formic acid to achieve a final concentration of formic acid of one percent. 
 The long-term stability of zyklophin in plasma was conducted at Celerion (Lincoln, NE). 
Plasma samples were prepared in CD1 mouse plasma supplied by BioreclamationIVT and were 
fortified with formic acid to achieve a final formic acid concentration of one percent. Six 
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replicates at 10 and 1000 ng/mL were tested following a 2 month storage at -80°C. Relatively 
small losses of zyklophin were observed at 10 ng/mL (11 ± 1%) or 1000 ng/mL (2.5 ± 0.7%). 
2.6.3 LC-MS/MS Analysis 
 Liquid chromatography was performed using an ACE C18 column (5μm, 50 x 3.0 mm),  
supplied by MAC-Mod, with a flow rate of 0.2 mL/min and an injection volume of 30 µL using 
a Waters Acquity Classic UPLC (Waters Corp.,  Milford MA) coupled to a triple quadrupole 
mass spectrometer (Quattro Ultima Micromass Ltd. Manchester UK) operating in the positive-
ion mode. The peptides were separated using the following gradient of aqueous 0.08% formic 
acid in water (mobile phase A) and acetonitrile containing 0.08% formic acid (mobile phase B): 
0 min (1% B), 5 min (60% B), and 7 min (1% B). From time 0 min to 5 min the %B was 
increased with a profile curve of 9. From time 5 min to 7 min the %B was decreased with a 
profile curve of 6 (see Figure 2.9). 




m/z 470.5, and its internal standard [M+4H]
4+
, 
m/z 345.0, were first isolated and then subjected to collision-induced dissociation to give their 
fragment ions. Data acquisition was carried out with Mass Lynx 4.1 software with the following 
settings: capillary voltage, 2800 V; cone voltage, 25 V; source temperature, 100 °C; desolvation 
temperature, 200°C; cone gas flow, 82L/h; desolvation gas flow, 1157 L/h. Q1 and Q3 resolution 
were 0.8uFWHH. The argon filled collision cell pressure was 1.63 × 10
-3
 mbar on a gauge in-line 
with the cell. Multiple-reaction-monitoring was used for zyklophin [M+3H]
3+ 
m/z 470.5  91.2 
and 226.3, and for the internal standard [M+4H]
4+
 m/z 345.0  150.2 with a collision energy of 
25 eV and dwell time of 0.3 s (see Figure 2.3). 
2.6.4 Sample Preparation  
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 Stock and working solutions of zyklophin and internal standard were prepared in 
polypropylene tubes with Milli-Q water. The calibration standards were prepared freshly in 
blank (drug-free) mouse plasma using the zyklophin working solution. The plasma calibration 
curve consisted of: zero standard, 10, 15, 25, 50, 100, 200, 500, and 1000 ng/mL. See Figure 2.5. 
To a mixture of 25μL of ice-cold plasma and 25μL of ice-cold internal standard (500 ng/mL 
prepared in ultrapure water) was added ice-cold acetonitrile (200μL) to precipitate the proteins 
out of solution. Following the precipitation, samples were vortexed and centrifuged at 10,000 
rpm for 10 minutes. Immediately following centrifugation, 150μL of the supernatant was dried 
down in a speed vacuum concentrator. The residue was then reconstituted in 75μL of 0.1% 
formic acid and analyzed by LC-MS/MS according to the method described above.  
2.6.5 Results and Discussion 
Previous attempts by Professor Aldrich’s lab to determine the pharmacokinetic properties 
of zyklophin by LCMS/MS were unsuccessful. The main obstacles encountered were 
irreproducibility of retention times, lack of resolution of zyklophin, and undesirable peak shape. 
This was believed to be due to the column employed during LC-MS/MS analysis and possible 
interaction with other components in the sample (e.g. lipids) that affected the column. In these 
studies, protein precipitation by acetonitrile proved to be a quick efficient method for sample 
cleanup prior to LCMS/MS analysis. Acetonitrile was selected due to its high efficiency at 
precipitating proteins in mouse plasma [9]. As seen in Figure 2.5, the standard curved showed 
good linearity resulting in good quantitation of the plasma samples. 
Retention and peak shape issues were resolved by using a different reversed phase 
column and changing the elution following injection into the LC system. In this work, an 
isocratic approach was initially tested, but did not provide adequate separation or retention in 
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various compositions of acetonitrile and ultrapure water. Next, a convex gradient approach was 
attempted where the composition of B would rapidly replace A. However, as with an isocratic 
LC method, adequate separation and retention was not achieved. Finally, a concave gradient 
approach (see Figure 2.9) was employed where the composition of B slowly replaces A. 
As seen in Figure 2.4, two product ions channels for zyklophin were evaluated during 
quantitation. The product ion with an m/z of 91 was utilized for quantitation due to the consistent 
reproducibility of this ion’s prescence throughout multiple samples. The product ion with an m/z 
of 226 did not exhibit consistent intensity throughout the multiple sample run. Additionally, as 
seen in Figure 2.6, a peak at the retention time of zyklophin is present in the zero standard. This 
peak, along with the lack of reproducibility of the 226 ion, indicate that there is a matrix effect 
that is affecting its analysis and quantitation. 
See Figure 2.8 for comparison of chromatograms of zyklophin 15 minutes post 3 mg/kg 
subcutaneous injection. The top chromatogram is from this work and the bottom chromatogram 
is from the previous attempt to characterize the pharmacokinetic properties of zyklophin. As can 
be seen from Figure 2.8, peak resolution is greatly increased, resulting in reliable quantitation 
with an LLOQ of 10 ng/mL. The method described in this chapter was then applied to 
investigate the pharmacokinetics of zyklophin following subcutaneous administration.  The 
results of theses studies are given in Chapter 3.  
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Figure 2.4 Structure of zyklophin (top structure) and internal standard (bottom) 
([NMe-Tyr
1
]dynorphin A-(1-11) amide) precursor and product ions  
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Figure 2.5: Standard calibration curve of zyklophin in mouse plasma 
 




Figure 2.7: Selected zyklophin standard chromatograms at 0, 10, and 1000 ng/mL. (The 
retention time of zyklophin is typically 4.5-4.6 minutes and the IS retention time is typically 4.7-








Figure 2.8: Comparison of chromatograms following 3 mg/kg subcutaneous injection. The top 
chromatogram is from this work. The bottom chromatogram (provided by Dr. Jane Aldrich’s  
lab – University of Florida) is from the previous attempt to characterize the pharmacokinetic 




Figure 2.9: Gradient elution profiles. In this work, a concave (9) profile was used for the 
increase of % B in the mobile phase from time 0 minutes (1% B) to time 5 minutes (60% B). A 
linear (6) profile was used for the decrease of % B in the mobile phase from time 5 minutes 
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Pharmacokinetics of Zyklophin via Subcutaneous Administration 
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3.1 Introduction to Pharmacokinetics 
The field of pharmaceutics is concerned with factors that influence the stability of a drug 
within the drug product, the release of drug from the drug product, the rate of dissolution and 
release of the drug at the adsorption site, and the delivery of drug to the site of action. Drug 
products are dosage forms with specific drug delivery systems that release and deliver the drug 
to the site of administration. Pharmaceuticals are substances intended for use in the diagnosis, 
cure, mitigation, treatment, or prevention of disease. Pharmaceuticals can be administered via a 
variety of dosage forms. The different types of dosage forms include capsules, tablets, liquids, 
and suspensions. Drug products are evaluated for safety, efficacy, and convenience for the 
targeted population. Biopharmaceutics is a field that investigates the relationship between the 
physical/chemical properties of a drug, drug product and route of administration on the rate and 
extent of drug absorption. 
As mentioned above, drugs can be delivered via various routes of administration. The 
drug is released from the drug product following administration and a fraction of the drug is then 
absorbed into surrounding tissue. This can either be directly from the site of administration 
(subcutaneous) or in the GI tract (oral). It then enters the bloodstream and once it reaches the site 
of action, a pharmacologic response results as long as the drug concentration is greater than or 
equal to the minimum effective concentration. 
In order to investigate a new drug substance, drug bioavailability is evaluated following 
administration by different routes in animal subjects prior to human studies. Pharmacologic, 
toxic, and clinical responses for the different doses and modes of administration are assessed in 
the initial experiments. Drug bioavailability can differ widely depending on the formulation, 
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even for the same route of administration. As a result, therapeutic effectiveness can vary between 
different formulations containing the same drug. The chemical properties of the drug molecule, 
route of administration, identity of metabolites and the degree of metabolism can determine 
whether an administered drug is therapeutically effective, toxic, or has no observable effect. 
The US Food and Drug Administration (FDA) must approve all drug products that intend 
to be marketed in the United States. Therefore, pharmaceutical manufacturers are required to 
perform extensive development and clinical research of drug effects in both animals and humans 
prior to approval. Biopharmaceutics provides the scientific basis for peptide, protein, and 
oligonucleotide based drug product design and development. Studies of biopharmaceuticals use 
both in vitro and in vivo methodologies. In vitro methods do not involve the dosing of animals or 
humans. In vivo methods are complex studies that test drug exposure within living animals and 
humans. In this work, a mouse model was used to determine the bioavailability of zyklophin 
following subcutaneous administration. 
As mentioned before, after drug is released from the drug product it is absorbed into the 
surrounding tissue or the blood. The distribution of the drug throughout an organism, its 
metabolism and ultimate elimination, can vary significantly from person to person and from 
animal-to-animal. However, the general behavior of a drug in vivo can be characterized using 
statistical models. The field of pharmacokinetics encompasses the study of the kinetics of drug 
absorption, distribution, and elimination via metabolism and excretion. Pharmacokinetic models 
are used to determine the rate of drug absorption, distribution and elimination. Therefore 
pharmacokinetics is a crucial step in the determination of the dosage levels needed for an 
effective therapeutic without toxicity. 
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The development of pharmacokinetic profiles involves both experimental and 
computational approaches. The experimental part involves the collection of blood samples at 
defined intervals following drug administration. Urine is also often collected and analyzed to 
identify metabolites. To perform PK studies, it is important to have robust analytical methods 
that can be used to quantify the drug in plasma, serum, and urine samples. The computational 
approach involves modeling of the ADME process using the plasma, urine, and fecal 
concentrations of the drug. The biological data is graphed (e.g. plasma drug concentration vs. 
time of collection) and then the drugs behavior is analyzed computationally to predict the 
pharmacokinetic and pharmacodynamics properties of the drug. 
Oral dosing is the most common and accepted route of drug administration and is 
normally associated with a high level of patient compliance. However, most peptides are not 
stable in the GI tract since it is designed for the digestion and adsorption of proteins. Its primary 
role is to bring nutrients and fluids into the body, while protecting against toxins, pathogens, and 
antigens [1]. The same processes that protect us from undesirable substances hamper the 
absorption of pharmaceuticals following oral administration. A physical barrier exists in the 
intestinal lining that is composed of: cell membranes, tight junctions between epithelial cells, a 
phospholipid bi-layer, mucus, efflux systems, and luminal enzymes. 
 Four main physical barriers have been reported as impeding the absorption of peptide-
based pharmaceuticals in the GI tract [2]. These barriers are: (1) the unstirred water layer, (2) the 
membranes of the intestinal epithelial cells, (3) tight junctions, and (4) a mucosal layer as seen in 
Figure 3.1. Epithelial cells of the intestine are covered by a hydrophilic aqueous boundary 
consisting of water, mucus, and glycocalyx [1]. This layer is known as the unstirred water layer. 
The unstirred water layer has been shown to be of limited importance as a barrier in the in vivo 
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process to both actively and passively absorbed solutes [3]. However, the mucus element of this 
layer can restrict drugs from reaching the epithelial surface. This is due to the composition of the 
mucus itself. Glycoproteins (mucins) are the major component of the mucus and these can 
stabilize the unstirred water layer by interacting with diffusing molecules and components 
through steric, interactive, and dynamic properties [4,5]. 
 The next physical barriers to be considered are the membranes of the intestinal epithelial 
cells and tight junctions between the cells. The intestinal epithelium is composed of columnar 
cells that include a combination of enterocytes, goblet cells, endocrine cells, and Paneth cells [6]. 
Passive diffusion, carrier-mediated transport, or vesicular transport are the only means by which 
a drug can be absorbed via the transcellular pathway. Lipid-soluble molecules can passively 
diffuse across plasma membranes. However, in order to move across cell membranes, a drug 
needs to have the appropriate size, charge, hydrogen bonding potential, and solution 
conformation [7]. These requirements are summarized in what is known as Lipinski’s Rule of 
Five [8]. Lipinski’s rule states that for a drug to have high oral bioavailability it cannot violate 
more than one of the following criteria: no more than 5 hydrogen bond donors, no more than 10 
hydrogen bond acceptors, a molecular mass less than 500 Daltons, and a log P less than 5. Thus 
molecules that are large or highly charged cannot pass through membranes unless they are 
transported via an active transport carrier. Since peptides typically have high molecular weight, 
they are hindered with regards to their passive diffusion through intercellular spaces and are 
almost always actively transported. 
 Movement of large molecules through the intercellular spaces is also prevented by tight 
junctions. The para-cellular pathway of drug absorption involves an aqueous extracellular route 
through the intercellular spaces between adjacent epithelial cells. Due to the absence of 
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proteolytic activity, this pathway has seen recent interest in the delivery of peptides [9]. However, 
hydrophobic intercellular material circumscribes each intestinal epithelial cell to form a seal that 
restricts diffusion of molecules according to size and charge [7,10]. These junctional complexes 
consist of three parts: tight junctions, adherens junctions, and spot desmosomes [11]. The tight 
junction is the only junction that has the potential to occlude. It controls diffusion of solutes 
through the para-cellular route and maintains polar distributions of the plasma membrane 
proteins at apical and basolateral surfaces [12,13]. 
 
Figure 3.1 Main physical barriers of the GI tract 
In addition to physical barriers, biochemical barriers exist. Degradation of peptides 
within the lumen of the GI tract can occur due to metabolism by digestive enzymes or luminal 
microorganisms. The enzymatic barrier is a critical impediment to overcome when considering 
the delivery of peptide pharmaceuticals. Enzymes in the GI tract catalyze digestive processes 
through hydrolytic cleavage of peptide bonds and chemical modifications. Proteolysis starts in 
the stomach in the presence of pepsin and occurs throughout the entire intestine. Enzymes 
released in the pancreas account for the majority of the luminal degradation of peptides, and 
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proteases are present in most anatomical sites, leaving peptides vulnerable to degradation 
throughout the body. Furthermore, instability in acidic environments is also a concern for oral 
peptide delivery. The pH in different parts of the GI tract varies from 1.5 to 8.5, and as a result, 
hydrolysis can be a concern for drugs that are pH-dependent. 
Physical and biochemical barriers cannot fully explain the barrier function of intestinal 
mucosa. Efflux systems (e.g. P-glycoprotein) along with intracellular metabolism can 
significantly contribute to poor bioavailability of peptides [7]. Active efflux is a biochemical 
mechanism that moves compounds out of a cell. Some efflux systems are drug specific and can 
result in the removal of the drug, contributing to poor availability. P-glycoprotein (P-gp) is an 
efflux protein located in the apical domain that pumps compounds from within the cell into the 
intestinal lumen [14]. Many drugs have been found to be substrates, inhibitors, or inducers of    
P-gp [15]. 
3.2 Animal Models 
Animal models are used in various stages of drug development to aid in the assessment of 
drug absorption, toxicity, exposure, and potential drug-drug interactions. In vivo animal studies, 
when done in concert with in vitro model systems, can be extrapolated to develop human dosing 
regimens for clinical testing. When considering pharmacokinetics, the animal model that is used 
must have similar biochemical and physiological systems governing drug adsorption, distribution, 
metabolism, and excretion (ADME) to humans. It is not possible to predict PK parameters of a 
drug from an animal model alone. However, using the correct animal model makes it possible to 
extrapolate dosage, duration, and toxicity into humans. 
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 An example of an animal model that is widely used for PK studies are rodents, including 
rats and mice. Rodents are categorized as gastric-acid secretors and are used in the study of pH-
sensitive adsorption. Intestinal permeability of humans and rodents can be correlated for drugs 
that passively diffuse through the enterocytes. It has been shown that a correlation of drug 
intestinal permeability exists between human and rat small intestine regarding both carrier 
mediated absorption and passive diffusion mechanisms [16]. This is due to similar gene 
expression of many common transporters between the human and rat duodenums. Multidrug 
resistance protein-3 (MDR-3) and glucose transporter 1 and 3 are similarly expressed in both 
human and rat intestine [16]. Additionally, rodents and humans exhibit similar expressions of 
metabolizing enzymes in the intestines and the liver [16]. Therefore, rodent models are suitable 
in the prediction of drug absorption. 
Absorption enhancers are compounds that disrupt the intestinal barrier allowing a drug to 
penetrate the epithelial cells [17]. However, disruption of the intestinal barrier can cause tissue 
damage and as a result, absorption enhancers must meet specific criteria. These include: 
reproducible drug absorption, predictable drug permeation, low toxicity, knowledge of the 
mechanism of action of the absorption enhancer, and reversible/minimal tissue damage. To 
mitigate the biochemical barrier, enzyme inhibitors can be used. However, the use of enzyme 
inhibitors has several drawbacks including disturbance of the digestion of proteins, stimulation 
of protease secretion, and various adverse events have been documented. Therefore, the 
challenge with this approach has been the development of a controlled, localized delivery of both 
drug and inhibitor [18]. 
3.3 Delivery of Peptide-Based Pharmaceuticals 
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Some of the advantages and disadvantages of peptides as drugs, compared to small 
molecule drugs, are summarized in Table 3.1. Despite the disadvantages listed in the table, many 
peptide-based drugs have already reached the market.  Analysis of the structural data for 
synthetic peptides [19] shows that the majority of current peptide-based synthetic products 
consist of 8–10 amino acids. Almost invariably, commercially available peptide therapeutics are 
delivered via injection or IV infusion due to the low oral bioavailability of these types of 
molecules. However, a major driving force for the interest in peptides and proteins as drugs is 
that they bind with high specificity to their in vivo targets, resulting in high potency of action. 
Peptides interact specifically with biological receptors making them potent endogenous 
hormones, growth factors, neurotransmitters and signaling molecules. In principle peptides could 
have many valuable applications in medicine but so far applications of synthetic peptides have 
been severely limited by their low systemic stability, high clearance, poor membrane 
permeability, negligible activity when administered orally, and high manufacturing costs. 
Advantages Disadvantages 
High potency Poor metabolic stability 
High selectivity Poor membrane permeability 
Broad range of targets High production costs 
Potentially lower toxicity than small molecules Rapid clearance 
Low accumulation in tissues Poor solubility 
High chemical/biological diversity Poor oral bioavailability 
Table 3.1 Advantages and disadvantages of peptide-based pharmaceuticals 
 Despite their drawbacks, peptides are becoming increasingly important in the systemic 
treatment of certain conditions [2,20]. Most drugs with a peptidomimetic structure are difficult to 
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deliver orally because of poor stability in the gastrointestinal (GI) tract and low membrane 
permeability [21-23]. However, most patients find injections to be uncomfortable and difficult. 
This can lead to poor compliance regarding administration.  
 Strategies for overcoming both physical and biochemical barriers for administration of 
peptide pharmaceuticals include many different approaches: chemical modification, pro-drug 
delivery, targeted delivery, co-administration of enzyme inhibitors, absorption enhancers, and 
interfering with ATP hydrolysis [24]. However, attempts to overcome the enzymatic barrier 
alone have met little success [25]. This is because many factors are in play when considering the 
pharmacokinetics of peptide drugs. Thus the goal of peptide delivery is to overcome both the 
physical and biochemical barriers through chemical modifications of the peptide. 
 There are many strategies for delivery of peptide pharmaceuticals. These include but are 
not limited to: prodrug development, structural modifications, and the addition of absorption 
enhancers or enzyme inhibitors. A prodrug is a pharmacologically inactive derivative of a parent 
drug that must be transformed in the body into metabolites that have pharmacologic activity. 
Prodrugs are designed to overcome limitations of the parent drug. Most prodrug approaches 
applied to peptides have focused on modification of functional groups in the C-terminus. With 
cyclic prodrugs, C-terminal carboxyl and N-terminal amino groups are protected from 
carboxypeptidases and aminopeptidases through the formation of a ring structure [26]. Cyclic 
modifications also limit the amount of hydrogen bonding in aqueous environments, increasing 
the ability of the molecule to diffuse across the mucosa of the GI tract. 
 Two common approaches to chemical modification of peptides, for overcoming both 
physical and biochemical barriers, is the attachment of polyethylene glycol (PEG) and 
51  
lipidization conjugation. PEGylation has been shown to improve biologic and pharmacologic 
properties of peptides [27]. Due to the favorable characteristics of PEG, the FDA has approved 
PEG modified drugs for IV, oral and dermal delivery. The attachment of PEG to peptide drugs 
has shown to decrease enzymatic activity, immunologic response, and overall clearance [28]. 
Lipidization is the conjugation of a fatty acid to a peptide. This method allows for the 
regeneration of the active peptide in tissues and the blood through the process known as 
reversible aqueous lipidization (REAL) and can be delivered in aqueous solutions. REAL 
modified peptides have been shown to increase GI stability, epithelial absorption, and plasma 
half-life [29]. 
 Subcutaneous administration of zyklophin (1-3 mg/kg)  has been previously explored 
[30]. Following SC administration, the compound showed dose dependent antagonism of  
antinociception induced by the KOR agonist in U50,488 in mice as determined via a 55°C warm 
water tail withdrawal assay. Zyklophin had no effect on morphine mediated antinociception. This  
further demonstrated its high KOR selectivity. Additionally, subcutaneous administration of 
zyklophin prevented stress-induced reinstatement of cocaine-seeking behavior in a conditioned 
place preference assay [30]. 
3.4 Experimental 
 As previously described in Chapter 2, adult male CD1 mice were obtained from the 
Jackson Laboratory (Bar Harbor, ME, USA). All mice were housed in accordance to the 
National Institute of Health Guide for Care and Use of Laboratory Animals. Adult male CD1 
mice, weighing 30-35g, were administered zyklophin by the subcutaneous route at 3 mg kg
-1 
in 
PBS. The dosing solution (0.100 mL) for the subcutaneous administration was geared to the 
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weight of the mice. The animals were sacrificed, and 1.0 mL of blood drawn at 15, 30, 60, 120, 
240, 480 and 720 min was immediately centrifuged at 15,000 rpm for 15 min to harvest plasma. 
The samples were kept on dry ice and processed on ice. Prior to storage at -80°C samples were 
treated with formic acid to achieve a final formic acid concentration of one percent. Plasma 
samples were analyzed according to methods described in Chapter 2. 
Liquid chromatography was performed using an ACE C18 column (5μm, 50 x 3.0 mm),  
supplied by MAC-Mod, with a flow rate of 0.2 mL/min and an injection volume of 30 µL using 
a Waters Acquity Classic UPLC (Waters Corp.,  Milford MA) coupled to a triple quadrupole 
mass spectrometer (Quattro Ultima Micromass Ltd. Manchester UK) operating in the positive-
ion mode. The peptides were separated using the following gradient of aqueous 0.08% formic 
acid in water (mobile phase A) and acetonitrile containing 0.08% formic acid (mobile phase B): 
0 min (1% B), 5 min (60% B), and 7 min (1% B). From time 0 min to 5 min the %B was 
increased with a profile curve of 9 (see Figure 2.9). From time 5 min to 7 min the %B was 
decreased with a profile curve of 6. 
The precursor ions of zyklophin [M+3H]
3+ 
m/z 470.5 and its internal standard [M+4H]
4+
 
m/z 345.0 were first isolated and then subjected to collision-induced dissociation to give their 
fragment ions. Data acquisition was carried out with Mass Lynx 4.1 software with the following 
settings: capillary voltage, 2800 V; cone voltage, 25 V; source temperature, 100 °C; desolvation 
temperature, 200°C; cone gas flow, 82L/h; desolvation gas flow, 1157 L/h. Q1 and Q3 resolution 
were 0.8uFWHH. The argon filled collision cell pressure was 1.63 × 10
-3
 mbar on a gauge in-line 
with the cell. Multiple-reaction-monitoring was used for zyklophin [M+3H]
3+ 
m/z 470.5  91.2, 
and for the internal standard [M+4H]
4+
 m/z 345.0  150.2 with a collision energy of 25 eV and 
dwell time of 0.3 s (see Figure 2.4). 
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Stock and working solutions of zyklophin and internal standard were prepared in 
polypropylene tubes with Milli-Q water. The calibration standards were prepared freshly in 
blank (drug-free) mouse plasma using the zyklophin working solution. The plasma calibration 
curve consisted of: zero standard, 10, 15, 25, 50, 100, 200, 500, and 1000 ng/mL. See Figure 2.5. 
To a mixture of 25μL of ice-cold plasma and 25μL of ice-cold internal standard (500 ng/mL 
prepared in ultrapure water) was added ice-cold acetonitrile (200μL) to precipitate the proteins 
out of solution. Following the precipitation, samples were vortexed and centrifuged at 10,000 
rpm for 10 minutes. Immediately following centrifugation, 150μL of the supernatant was dried 
down in a speed vacuum concentrator. The residue was then reconstituted in 75μL of 0.1% 
formic acid and analyzed by LC-MS/MS according to the method described above. 
3.5 Results and Discussion 
Zyklophin was administered to 33 CD1 mice by subcutaneous injection of 3 mg kg
-1
 in 
PBS. The mean plasma zyklophin reached a maximum concentration at 30 min post-dose. The 
peptide exhibited a maximal plasma concentration of 1.8 µg/mL with a high plasma clearance 
(see Table 3.3). See Table 3.2 regarding specific PK parameters for subcutaneous dosing of 
zyklophin. These results are consistent with the desired short duration kappa opioid receptor 
(KOR) antagonist activity in vivo of zyklophin (3 mg kg
-1
 administered subcutaneously), which 
lasts for less than 12 hours. Therefore, the selective KOR activity and favorable pharmacokinetic 





Dose tmax Cmax AUC t½ 
mg/kg Hr µg/mL hr ∙ µg/mL hr 
3 0.5 1.817 2.044 Unable to 
calculate 




Figure 3.2 Mean concentration vs. time PK profile (mean and standard deviation, n = 5 at each 
time point) of zyklophin following subcutaneous administration. See Table 3.3 for individual 


























4 Below LLOQ 
4 Below LLOQ 
4 Below LLOQ 
4 Below LLOQ 
4 Below LLOQ 
8 Below LLOQ 
8 Below LLOQ 
8 Below LLOQ 
8 Below LLOQ 
8 Below LLOQ 
12 Below LLOQ 
12 Below LLOQ 
12 Below LLOQ 
Table 3.3 Concentration data via LC/MS-MS of plasma samples following subcutaneous 
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4.1 Thesis Summary 
Peptide-based drugs have been shown to be successful pharmaceutical agents exhibiting 
high activity, high specificity, low toxicity, and minimal drug-drug interaction. However, 
peptide-based drugs have been under-utilized due to low oral bioavailability. Initial testing has 
shown that zyklophin crosses the blood brain barrier to antagonize the KOR in the CNS 
following in vivo administration. Zyklophin’s duration of activity following a systemic dose is 
less than 12 hours
 
where as a non-peptide KOR antagonist, such as nor-BNI, exhibits duration of 
activity up to 28 days after a single dose is administered. This prolonged activity of nor-BNI 
complicates its use as a pharmacological tool and as a potential therapeutic agent whereby 
increasing the importance of peptide-based KOR antagonist.
 
Due to modifications of the C-
terminus and address domain, zyklophin has an increased metabolic stability, high KOR 
selectivity, and antagonist activity. 
In this thesis, the pharmacokinetics of zyklophin following subcutaneous administration 
were investigated using LC-MS-MS. Zkylophin exhibited a maximal plasma concentration of 1.8 
µg/mL with a high plasma clearance (see Table 3.3). The subcutaneous PK results are consistent 
with the desired short duration kappa opioid receptor (KOR) antagonist activity in vivo of 
zyklophin (3 mg kg
-1
 administered subcutaneously), which lasts for less than 12 hours. Therefore, 
the selective KOR activity and favorable pharmacokinetic properties of zyklophin make it an 
ideal candidate for potential drug development for drug abuse. 
4.2 Future Directions 
Future investigations into the metabolism and distribution of zyklophin in vivo in 
biological tissues will be needed to further assess its potential as a pharmaceutical agent. Since 
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zyklophin shows promise as a treatment of cocaine addiction (short duration kappa opioid 
receptor (KOR) antagonist activity in vivo), the development of an appropriate formulation is 
necessary to ensure a high level of compliance. 
Microdialysis studies can be used to examine the site specific metabolism of zyklophin. If 
zyklophin is delivered peripherally, transport studies can be characterized by sampling via the 
microdialysis probe as the release of neurotransmitters can be investigated. By utilizing 
radiolabeling and scintillation counting, permeation studies can be conducted to determine if 





HLB Sample Preparation Method – Zyklophin 
1. 25 µL of plasma sample (blank plasma for control blanks and zero standard) 
2. 25 µL of internal standard (prepared in ultrapure water) 
3. 200 µL of ultrapure water 
4. Vortex and centrifuge for 10 minutes at 5000 rpm 
5. Rinse an Oasis HLB 96-well Plate, 30 mg Sorbent per Well, 30 µm Particle Size with 
200 µL ACN. 
6. Rinse with 200 µL MeOH. 
7. Wet with 200 µL ultrapure water. 
8. Load 150 µL sample. 
9. Wash with 200 µL ultrapure water. 
10. Wash with 200 µL 0.1% formic acid. 
11. Wash with 1% ACN. 
12. Wash with 5% ACN. 
13. Elute with 100% MeOH. 
14. Dry down with sample concentrator. 
15. Reconstitute residue with 75 µL 0.1% formic acid. 
16. Inject onto LC-MS/MS platform. 
